{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=60",
    "query": {
      "intervention": "Placebo once daily",
      "page": 60
    },
    "page_size": 10
  },
  "pagination": {
    "page": 60,
    "page_size": 10,
    "total_count": 5508,
    "total_pages": 551,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=61&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=59&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T00:19:39.262Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06997484",
      "title": "First-in-Human Single and Multiple Dose of HL-400",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson Disease"
      ],
      "interventions": [
        {
          "name": "HL-400",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Highlightll Pharmaceutical (USA) LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 86,
      "start_date": "2025-04-25",
      "completion_date": "2026-10-27",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-10-31T00:19:39.262Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06997484"
    },
    {
      "nct_id": "NCT01631487",
      "title": "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "JNJ-39439335 10 mg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-39439335 25 mg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-39439335 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "20 Years to 55 Years · Male only"
      },
      "enrollment_count": 86,
      "start_date": "2012-07",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2013-06-25",
      "last_synced_at": "2026-10-31T00:19:39.262Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01631487"
    },
    {
      "nct_id": "NCT05564390",
      "title": "MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm",
        "Acute Myeloid Leukemia Post Cytotoxic Therapy",
        "Acute Myeloid Leukemia, Myelodysplasia-Related",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Chest Radiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin",
          "type": "DRUG"
        },
        {
          "name": "Daunorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Decitabine and Cedazuridine",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Emavusertib",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Enasidenib",
          "type": "DRUG"
        },
        {
          "name": "Epoetin Alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Gemtuzumab Ozogamicin",
          "type": "DRUG"
        },
        {
          "name": "Gilteritinib",
          "type": "DRUG"
        },
        {
          "name": "Liposome-encapsulated Daunorubicin-Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Luspatercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Mutation Carrier Screening",
          "type": "PROCEDURE"
        },
        {
          "name": "Olutasidenib",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Quizartinib",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2000,
      "start_date": "2024-06-18",
      "completion_date": "2029-05-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-10-31T00:19:39.262Z",
      "location_count": 347,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 265 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05564390"
    },
    {
      "nct_id": "NCT00932646",
      "title": "Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "BI 1744 (Olodaterol) Low Dose",
          "type": "DRUG"
        },
        {
          "name": "BI 1744 (Olodaterol) Medium Dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Foradil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2009-06",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2016-02-05",
      "last_synced_at": "2026-10-31T00:19:39.262Z",
      "location_count": 13,
      "location_summary": "Jasper, Alabama • Clearwater, Florida • DeLand, Florida + 10 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Austell",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00932646"
    },
    {
      "nct_id": "NCT01053988",
      "title": "A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "FF/GW642444 Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "FF Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "GW642444 Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1031,
      "start_date": "2009-10-05",
      "completion_date": "2011-04-14",
      "has_results": true,
      "last_update_posted_date": "2018-07-12",
      "last_synced_at": "2026-10-31T00:19:39.262Z",
      "location_count": 47,
      "location_summary": "Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 42 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01053988"
    },
    {
      "nct_id": "NCT02558296",
      "title": "Bexagliflozin Efficacy and Safety Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Bexagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theracos",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1700,
      "start_date": "2015-10",
      "completion_date": "2019-10-23",
      "has_results": true,
      "last_update_posted_date": "2021-07-14",
      "last_synced_at": "2026-10-31T00:19:39.262Z",
      "location_count": 66,
      "location_summary": "Gilbert, Arizona • Little Rock, Arkansas • Azusa, California + 57 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02558296"
    },
    {
      "nct_id": "NCT00833703",
      "title": "Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Defects, Congenital"
      ],
      "interventions": [
        {
          "name": "Clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Months and older"
      },
      "enrollment_count": 49,
      "start_date": "2009-01",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2011-08-22",
      "last_synced_at": "2026-10-31T00:19:39.262Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00833703"
    },
    {
      "nct_id": "NCT00782288",
      "title": "Phase II Study of Digitoxin to Treat Cystic Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "digitoxin",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Jewish Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2010-08",
      "completion_date": "2016-08",
      "has_results": true,
      "last_update_posted_date": "2022-04-21",
      "last_synced_at": "2026-10-31T00:19:39.262Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00782288"
    },
    {
      "nct_id": "NCT00772603",
      "title": "Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsies, Partial"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "2400mg SPN-804",
          "type": "DRUG"
        },
        {
          "name": "1200mg SPN-804",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 366,
      "start_date": "2008-11",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2014-02-11",
      "last_synced_at": "2026-10-31T00:19:39.262Z",
      "location_count": 23,
      "location_summary": "Huntsville, Alabama • Northport, Alabama • Phoenix, Arizona + 20 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00772603"
    },
    {
      "nct_id": "NCT00986960",
      "title": "Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "repository corticotropin injection",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University at Buffalo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2009-12",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2021-01-05",
      "last_synced_at": "2026-10-31T00:19:39.262Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00986960"
    }
  ]
}